Skip to main content

Advertisement

SpringerLink
Log in

Apocrine metaplasia of breast cancer: clinicopathological features and predicting response

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Tailor-made therapies are currently gaining prominence, and the clarification of predictive markers for anticancer agents represents an important research issue. From our institutional neoadjuvant experience, apocrine carcinoma showed a high correlation with therapeutic effect against breast cancer. We thus considered that apocrine metaplasia (AM) might represent a predictive marker for breast cancer.

Methods

A total of 210 primary invasive breast cancers from Japanese patients were scored according to the size of cytoplasmic granules and abundance of cytoplasm, then classified into three categories: non-AM, incomplete AM and complete AM. Clinicopathological features were evaluated based on these classifications.

Results

Distribution according to the classification of AM was: non-AM, 61%; incomplete AM, 36%; and complete AM, 3%. No significant differences with regard to estrogen receptor, progesterone receptor, human epidermal growth factor receptor type 2, androgen receptor or bcl-2 were observed among the three groups. Gross cystic fluid protein-15 showed a high positive rate (83%) for complete AM. Cases of incomplete AM and complete AM were combined to form the AM group. Among lymph node-positive patients without chemotherapy, the 10-year recurrence-free survival (RFS) rate was 85% for non-AM and 44% for AM (p < 0.05). Conversely, among the lymph node-positive group with chemotherapy, the 10-year RFS rate was 45% for non-AM and 75% for AM (p < 0.05). Prognoses for non-AM and AM were turned around by chemotherapy. Lymph node metastasis was related to prognosis in multivariate analysis, although AM did not remain an independent prognosticator.

Conclusions

Apocrine metaplasia appears to offer an effective predictive marker for anticancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Abbreviations

AM:

Apocrine metaplasia

IDC-NST:

Invasive ductal carcinoma of no special type

RFS:

Recurrence-free survival

ER:

Estrogen receptor

PgR:

Progesterone receptor

HER2:

Human epidermal growth factor receptor type 2

AR:

Androgen receptor

CMF:

Cyclophosphamide, methotrexate and fluorouracil

GCDFP-15:

Gross cystic disease fluid protein-15

References

  1. O’Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology. 2008;52:3–10.

    Article  PubMed  Google Scholar 

  2. Takeuchi H, Tsuji K, Ueo H, Kano T, Maehara Y. Clinicopathological feature and long-term prognosis of apocrine carcinoma of the breast in Japanese women. Breast Cancer Res Treat. 2004;88:49–54.

    Article  PubMed  Google Scholar 

  3. Durham JR, Fechner RE. The histologic spectrum of apocrine lesions of the breast. Am J Clin Pathol. 2000;113:S3–18.

    CAS  PubMed  Google Scholar 

  4. Tavassoli FA, Devilee P, World Health Organization Classification of Tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press;2003.

    Google Scholar 

  5. Rosen PP. Apocrine carcinoma. In: Weinberg RW, Donnellan K, Palumbo R, editors. Rosen’s breast pathology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins;2001. p. 483–95.

    Google Scholar 

  6. Azzoparidi JG. Problems in breast pathology. Major problems in pathology. vol. 11. London: W.B. Saunders;1979.

    Google Scholar 

  7. Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am J Pathol. 1986;123:532–41.

    CAS  PubMed  Google Scholar 

  8. Mossler JA, Barton TK, Brinkhous AD, McCarty KS, Moylan JA, McCarty KS Jr. Apocrine differentiation in human mammary carcinoma. Cancer. 1980;46:2463–71.

    Article  CAS  PubMed  Google Scholar 

  9. Haagensen CD. Diseases of the breast. 3rd ed. Philadelphia: W.B. Saunders;1986.

    Google Scholar 

  10. Miller WR, Telford J, Dixon JM, Shivas AA. Androgen metabolism and apocrine differentiation in human breast cancer. Breast Cancer Res Treat. 1985;5:67–73.

    Article  CAS  PubMed  Google Scholar 

  11. Faratian D, Bartlett J. Predictive markers in breast cancer—the future. Histopathology. 2008;52:91–8.

    Article  CAS  PubMed  Google Scholar 

  12. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003;88:406–12.

    Article  CAS  PubMed  Google Scholar 

  13. Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, et al. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res. 2008;14:3494–502.

    Article  CAS  PubMed  Google Scholar 

  14. Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, et al. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer. 2007;110:509–17.

    Article  CAS  PubMed  Google Scholar 

  15. Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, et al. p-53 Gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol. 2007;18:997–1003.

    Article  CAS  PubMed  Google Scholar 

  16. Horii R, Akiyama F, Ito Y, Matsuura M, Miki Y, Iwase T. Histological features of breast cancer, highly sensitive to chemotherapy. Breast Cancer. 2007;14:393–400.

    Article  PubMed  Google Scholar 

  17. Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 2006;119:1927–33.

    Article  CAS  PubMed  Google Scholar 

  18. Aschele C, Lonardi S, Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev. 2002;28:27–47.

    Article  CAS  PubMed  Google Scholar 

  19. Moliterni A, Ménard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol. 2003;21:458–62.

    Article  CAS  PubMed  Google Scholar 

  20. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002;8:1107–16.

    CAS  PubMed  Google Scholar 

  21. Akiyama F, Horii R. Therapeutic strategies for breast cancer based on histological type. Breast Cancer. 2009;16(3):168–72.

    Article  PubMed  Google Scholar 

  22. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660–71.

    Article  CAS  PubMed  Google Scholar 

  23. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–23.

    Article  CAS  PubMed  Google Scholar 

  24. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.

    Article  CAS  PubMed  Google Scholar 

  25. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    Article  CAS  PubMed  Google Scholar 

  26. Haagensen CD, Bodian C, Haagensen DE Jr. Breast carcinoma: risk and detection. Philadelphia: W.B. Saunders;1981.

    Google Scholar 

  27. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.

    Article  CAS  PubMed  Google Scholar 

  28. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer V.I.2008.

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo, 135-8550, Japan

    Akiko Ogiya & Futoshi Akiyama

  2. Departments of Pathology, Medical Oncology and Breast Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo, 135-8550, Japan

    Rie Horii, Tomo Osako, Yoshinori Ito & Takuji Iwase

  3. Department of Human Pathology, Graduate School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyou-ku, Tokyo, 113-8510, Japan

    Yoshinobu Eishi

Authors
  1. Akiko Ogiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rie Horii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomo Osako
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshinori Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuji Iwase
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshinobu Eishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Futoshi Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akiko Ogiya.

About this article

Cite this article

Ogiya, A., Horii, R., Osako, T. et al. Apocrine metaplasia of breast cancer: clinicopathological features and predicting response. Breast Cancer 17, 290–297 (2010). https://doi.org/10.1007/s12282-009-0178-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-009-0178-9

Keywords

Search

Navigation